Copyright
©The Author(s) 2019.
World J Gastrointest Pathophysiol. Jan 5, 2019; 10(1): 1-10
Published online Jan 5, 2019. doi: 10.4291/wjgp.v10.i1.1
Published online Jan 5, 2019. doi: 10.4291/wjgp.v10.i1.1
Table 1 mACE2-rAAV2/8 therapy increased hepatic ACE2 expression, resulting in a marked reduction in biliary fibrosis in a long-term model of chronic biliary fibrosis (Mdr2-KO mice)
| Stage of the disease | Hepatic ACE2 expression, fold | Liver fibrosis reduction, % |
| Early: 3-6 mo | 60 | 50% |
| Advanced: 7-9 mo | 160 | 80% |
- Citation: Rajapaksha IG, Angus PW, Herath CB. Current therapies and novel approaches for biliary diseases. World J Gastrointest Pathophysiol 2019; 10(1): 1-10
- URL: https://www.wjgnet.com/2150-5330/full/v10/i1/1.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v10.i1.1